CytomX Therapeutics (CTMX) Competitors $1.09 -0.01 (-0.91%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CTMX vs. CTNM, PROC, SLRN, TNGX, KMDA, CGC, TRVI, ETON, AQST, and SAGEShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Contineum Therapeutics (CTNM), Procaps Group (PROC), Acelyrin (SLRN), Tango Therapeutics (TNGX), Kamada (KMDA), Canopy Growth (CGC), Trevi Therapeutics (TRVI), Eton Pharmaceuticals (ETON), Aquestive Therapeutics (AQST), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Contineum Therapeutics Procaps Group Acelyrin Tango Therapeutics Kamada Canopy Growth Trevi Therapeutics Eton Pharmaceuticals Aquestive Therapeutics Sage Therapeutics CytomX Therapeutics (NASDAQ:CTMX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends. Is CTMX or CTNM more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Contineum Therapeutics' net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% Contineum Therapeutics N/A -49.92%-20.52% Do insiders and institutionals have more ownership in CTMX or CTNM? 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in CTMX or CTNM? CytomX Therapeutics received 365 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 65.49% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% Contineum TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Do analysts recommend CTMX or CTNM? CytomX Therapeutics currently has a consensus target price of $5.77, suggesting a potential upside of 429.59%. Contineum Therapeutics has a consensus target price of $29.25, suggesting a potential upside of 116.67%. Given CytomX Therapeutics' higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has preferable earnings & valuation, CTMX or CTNM? Contineum Therapeutics has lower revenue, but higher earnings than CytomX Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$126.62M0.67-$570K$0.176.41Contineum Therapeutics$50M6.96$22.72MN/AN/A Does the media prefer CTMX or CTNM? In the previous week, Contineum Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for Contineum Therapeutics and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.06 beat Contineum Therapeutics' score of 0.63 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCytomX Therapeutics beats Contineum Therapeutics on 9 of the 16 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.30M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio6.4110.5089.8217.18Price / Sales0.67195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book-1.545.094.784.78Net Income-$570,000.00$151.83M$120.23M$225.60M7 Day Performance-1.80%-2.13%-1.92%-1.23%1 Month Performance25.79%-3.10%11.49%3.36%1 Year Performance-22.70%11.54%30.57%16.60% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.321 of 5 stars$1.09-0.9%$5.77+429.6%-18.7%$85.30M$126.62M6.41170News CoveragePositive NewsCTNMContineum Therapeutics1.9558 of 5 stars$13.69-2.4%$29.25+113.7%N/A$352.93M$50M0.0031News CoveragePROCProcaps Group0.8894 of 5 stars$3.09+28.2%N/A-20.3%$348.61M$414.10M5.105,500News CoverageSLRNAcelyrin2.7884 of 5 stars$3.44+6.5%$11.75+241.6%-55.8%$345.14MN/A-1.31135TNGXTango Therapeutics1.8563 of 5 stars$3.18+3.9%$13.14+313.3%-68.5%$341.59M$43.38M-2.5990News CoverageKMDAKamada3.8909 of 5 stars$5.84-0.5%$14.50+148.3%-1.2%$335.68M$158.38M20.96360Positive NewsCGCCanopy Growth2.4368 of 5 stars$3.07-1.3%$3.50+14.0%-41.0%$334.45M$220.27M-0.631,029Analyst RevisionNews CoverageTRVITrevi Therapeutics3.0363 of 5 stars$4.33+3.8%$9.31+115.1%+214.0%$332.85MN/A-10.2020Gap DownHigh Trading VolumeETONEton Pharmaceuticals2.1328 of 5 stars$12.88+4.3%$15.00+16.5%+176.9%$332.82M$31.64M-56.1420AQSTAquestive Therapeutics1.495 of 5 stars$3.62+0.3%$9.80+170.7%+95.2%$330.07M$50.58M-8.02160Analyst ForecastAnalyst RevisionNews CoverageGap DownSAGESage Therapeutics4.1504 of 5 stars$5.22-3.2%$11.53+120.9%-73.1%$319.31M$86.46M-0.97690 Related Companies and Tools Related Companies Contineum Therapeutics Competitors Procaps Group Competitors Acelyrin Competitors Tango Therapeutics Competitors Kamada Competitors Canopy Growth Competitors Trevi Therapeutics Competitors Eton Pharmaceuticals Competitors Aquestive Therapeutics Competitors Sage Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTMX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
